Track protection status across key markets to assess launch feasibility.
It is formulated by 2 pharmaceutical companies such as AMNEAL, PADAGIS US. It is marketed under 1 brand name, including TOBRAMYCIN AND DEXAMETHASONE. Available in 1 different strength, such as 0.1%;0.3%, and administered through 1 route including SUSPENSION/DROPS;OPHTHALMIC.
API availability: Loading API feasibility...
Licensing: 2 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"82526","ingredient":"DEXAMETHASONE; TOBRAMYCIN","trade_name":"TOBRADEX ST","family_id":"5bf41f458b694641848e","publication_number":"US8101582B2","cleaned_patent_number":"8101582","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-12-19","publication_date":"2012-01-24","legal_status":"Granted"} | US8101582B2 Formulation | 24 Jan, 2012 | Granted | 19 Dec, 2027 | |
{"application_id":"82528","ingredient":"DEXAMETHASONE; TOBRAMYCIN","trade_name":"TOBRADEX ST","family_id":"5bf41f458b694641848e","publication_number":"US8450287B2","cleaned_patent_number":"8450287","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-12-19","publication_date":"2013-05-28","legal_status":"Granted"} | US8450287B2 Formulation | 28 May, 2013 | Granted | 19 Dec, 2027 | |
{"application_id":"82527","ingredient":"DEXAMETHASONE; TOBRAMYCIN","trade_name":"TOBRADEX ST","family_id":"5bf41f458b694641848e","publication_number":"US7795316B1","cleaned_patent_number":"7795316","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-08-03","publication_date":"2010-09-14","legal_status":"Patented case"} | US7795316B2 Formulation | 14 Sep, 2010 | Patented case | 03 Aug, 2028 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Dexamethasone; Tobramycin
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.